ELV · Q3 2025 Earnings
CautiousElevance Health
Reported October 21, 2025
30-second summary
Elevance held FY25 adjusted EPS at ~$30 and benefit expense ratio at ~90% — but Q3's benefit expense ratio printed 91.3% (180bps YoY), reflecting elevated but expected Part D seasonality plus Medicaid acuity pressure. More consequential than the print: management used the Q&A to seed a 2026 outlook that includes at least a 125bps Medicaid margin decline year-over-year and roughly $1 of EPS in front-loaded technology and Carelon investments — the first concrete admission that 2026 is another reset year, not a recovery year. Critically, management explicitly anchored the 2026 modeling baseline at $27 (FY25 ~$30 less ~$3 of discrete, non-recurring favorables — primarily tax, the Q2 value-based provider settlement, and alternatives valuation gains in NII). The $27 baseline, not $30, is the starting point for any 2026 math. Management framed the spend as prioritizing "durable, long-term performance over near-term expense leverage" — a deliberate pivot from contrition to investment-led offense.
Headline numbers
EPS
Q3 FY2025
$6.03
Revenue
Q3 FY2025
$50.10B
+12.0% YoY
Operating margin
Q3 FY2025
2.6%
Key financials
Q3 FY2025| Metric | Q3 FY2025 | YoY | Q2 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $50.10B | +12.0% | $49.40B | +1.4% |
| EPS | $6.03 | — | $8.84 | -31.8% |
| Operating margin | 2.6% | — | 4.9% | -230bps |
Guidance
Elevance Health reaffirmed full-year FY2025 adjusted EPS and benefit expense ratio guidance with no changes to forward outlook; management remains disciplined on cost control and 2026 positioning.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Reaffirmed unchanged this quarter: Adjusted Diluted EPS (approximately $30.00), Benefit Expense Ratio (approximately 90.0%)
Segment KPIs
Q3 FY2025| Segment | Q3 FY2025 | YoY |
|---|---|---|
| Health Benefits | $42.2B | +10.4% |
| CarelonRx | $11B | +20.3% |
| Carelon Services | $7.3B | +57.9% |
| Medicare | $11.1B | +18.7% |
| Medicaid | $14.2B | +8.4% |
Other KPIs
Q3 FY2025| Segment | Q3 FY2025 |
|---|---|
| Medical Membership | 45.4 million |
| Medicare Advantage Membership | 2.245 million |
| Medicaid Membership | 8.645 million |
| Benefit Expense Ratio | 91.3% |
| Operating Expense Ratio | 10.5% |
| Adjusted Operating Expense Ratio | 10.4% |
| Days in Claims Payable | 42.6 days |
| CarelonRx Adjusted Scripts | 85.0 million |
Management tone
Q2: "second consecutive year of cuts" → Q3: discipline, affordability, 2026 trough framing.
From "no near-term recovery assumed" to explicit 2026 down-year quantification. Last quarter management refused to frame 2026 at all, calling it "still early." This quarter, in Q&A with AJ Rice and Justin Lake, management put a number on it: Medicaid margins down at least 125bps year-over-year in 2026, with 2026 framed as the trough, not the beginning of another reset period. The shift from silence to quantification is itself a tell — internal visibility has improved enough to put a stake in the ground, but the stake is in worse ground than the buyside had hoped. The anchor framing from Gail: "we are assuming that we enter the year at the place we exited the year" — i.e., the Q4 run rate informs the 2026 starting point, and Q4 is running hot.
The $27 baseline is the most important 2026 anchor. Both Gail and Mark explicitly directed investors to use $27 — not $30 — as the FY25 earnings baseline for 2026 modeling, stripping out ~$3 of discrete, non-recurring favorables (primarily tax actions, the Q2 value-based provider settlement, and alternatives valuation gains in net investment income). Layer on the ~$1 EPS of incremental investment headwind and the at-least-125bps Medicaid margin decline, and the buyside's 2026 starting point is materially lower than a naive "grow off $30" assumption would suggest.
From defensive contrition to investment-led offense. Q2 was contrite ("revising guidance for the second consecutive year is disappointing"). Q3 reframes the spend story: roughly $1 of EPS in 2026 going into AI, Carelon, and operational quality, with management explicit that they are prioritizing "durable, long-term performance over near-term expense leverage." This is a deliberate pivot from "we got hit" to "we are spending into the trough." Whether investors credit it depends on 2027 deliverables; the credibility account is overdrawn after two cut years.
On Medicaid rate cycles, a constructive but unresolved posture. Q2 framed states as "constructively responsive" but warned of "a couple of rate cycles" to catch up. Q3 adds operational detail: states are now discussing program changes (ABA, GLP-1 restrictions) alongside rate increases. The recovery is now framed as bilateral — rates plus benefit redesign — rather than pure rate catch-up. This is a more durable, if slower, path back to the 2-4% target margin band.
Policy externalities elevated to a first-order risk. ACA enhanced subsidy expiration is now flagged in Q&A as a "material contraction" risk citing CBO estimates, and OBBBA reconciliation is explicitly modeled as a 2027+ phenomenon. The combined message: 2026 is the trough on the operating cycle Elevance controls, but the policy cycle adds independent tail risk on top.
Q&A highlights
AJ Rice · UBS
Medicaid margin decline: Are states acknowledging the issue? Is Elevance unique in experiencing pressure? What are the specific pressure points (cost trend vs. rate updates vs. benefit design changes)?
Management confirmed that cost trend (elevated acuity and utilization from re-verification) and rate lag are the two anchors behind the 125 bps decline assumption. States are constructive in conversations and more receptive to program changes (e.g., ABA, GLP-1 restrictions) to reduce costs. States are exploring benefit modifications alongside rate discussions.
Stephen Baxter · Wells Fargo
What is the materiality of the several hundred million dollars in incremental 2026 investments? Is this transitory? How does this investment spending impact 2027 growth expectations?
Management quantified investments at approximately $1 EPS impact across three areas: technology/AI adoption, CareLine expansion, and operational/quality improvements (star ratings, member engagement). These are front-loaded investments expected to create operating leverage and improve long-term performance. Gail emphasized AI embedding at scale with tangible examples (personalized match for members, reduced denials 68%, reduced peer-to-peer reviews).
Lisa Gill · J.P. Morgan
ACA enhanced subsidies: What is the membership impact if enhanced subsidies expire? How should investors model 2026 ACA membership under different policy scenarios?
Management declined to provide specific membership estimates but acknowledged material contraction risk if subsidies expire, citing Congressional Budget Office estimates of meaningfully lower enrollment and higher acuity risk pools. Gail emphasized Elevance is prepared for multiple scenarios (extension, modification, or expiration) and pricing reflects higher acuity. Mark noted smaller, more acute pools create adverse dynamics (fewer enrollees to spread risk, sharper premium increases).
Justin Lake · Wolf Research
Medicaid margins: How much worse are Q4 2025 margins than the full-year negative 50 bps? What is the exit run rate going into 2026 for the 125 bps decline comparison?
Management acknowledged margins deteriorated through 2025 and Q4 is likely worse than full-year average. However, management framed 2026 as the trough given intensive care management (behavioral health, specialty pharmacy, LTSS), expecting sequential improvement from 2026 into 2027. Management assumes entering 2026 at the place exiting 2025, establishing the baseline for the 125 bps decline.
Kevin Fishbeck · Bank of America
Medicaid risk pool shifts: How much of the reconciliation bill risk pool shifts (from a 5-year provision) is pulled forward into 2026? When management says 'return to balanced growth in 2027,' does that mean normal growth algorithm or something less?
Management clarified that OBRA implementation impacts are phased and manageable, with less than 20% of membership impacted primarily in 2027-2028. 'Balanced growth in 2027' means return to the normal historical growth algorithm with contributions from commercial, government, and CareLine supported by operating leverage and disciplined capital deployment. Expects more evenly distributed earnings drivers in 2027.
Answers to last quarter's watch list
What to watch into next quarter
The Q4 benefit expense ratio bridge to FY ~90%: Q3 at 91.3% and Q4 expected worse on Medicaid means the FY guide implicitly requires either reserve releases, ACA cohort favorable development, or a sharp commercial-mix shift. Watch whether Q4 prints sub-90% or whether the FY guide is missed at the print.
2026 EPS range off the $27 baseline: management quantified Medicaid headwind (-125bps) and investment headwind (~$1 EPS) and anchored modeling at $27, without providing a 2026 EPS number. The Q4 call is the natural inflection — watch whether they introduce a 2026 EPS range, and whether the long-term 12% algorithm is reaffirmed, softened, or quietly dropped.
Medicaid Q4 exit rate: management explicitly anchored the 2026 trend assumption to the Q4 2025 exit rate. Watch the Q4 Medicaid operating margin disclosure — a worse-than-expected Q4 exit shifts the 2026 starting point lower.
Carelon Services deceleration: +57.9% YoY this quarter vs. +63.7% last quarter. Watch whether the deceleration continues toward a more normalized 30-40% range and whether segment margin disclosure reveals scaling pressure.
ACA enhanced subsidy outcome and membership re-pricing: by Q4 the policy outcome should be largely resolved. Watch the 2026 ACA membership disclosure and whether pricing was sufficient for the acuity actually retained.
Medicare Advantage margin trajectory: MA membership ticked down slightly QoQ (2.255M → 2.245M) but is up 9.7% YoY, consistent with disciplined exits in service areas affecting ~150k members. Watch whether Q4 disclosure quantifies progress toward target MA margins on the narrower book.
Sources
- Elevance Health Q3 FY2025 Earnings Release: https://www.sec.gov/Archives/edgar/data/1156039/000119312525244191/d270615dex991.htm
- Elevance Health Q3 FY2025 earnings call Q&A excerpts (extracted)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.